Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria

Basit Öğe Kaydı
dc.authoridKAYA, OZGE/0000-0001-8062-1664
dc.authoridKESKINKAYA, ZEYNEP/0000-0002-2982-3823
dc.contributor.authorKeskinkaya, Zeynep
dc.contributor.authorKaya, Ozge
dc.contributor.authorMermutlu, Selda Isik
dc.contributor.authorOgretmen, Zerrin
dc.date.accessioned2025-01-27T20:38:46Z
dc.date.available2025-01-27T20:38:46Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: Two distinct chronic spontaneous urticaria (CSU) endotypes, IgE-mediated autoallergic and IgG-mediated autoimmune, were defined based on the response patterns to omalizumab. However, the coexistence of IgE and IgG autoantibodies in a subset of patients might complicate the prediction of the treatment outcomes. This study aimed to evaluate the effectiveness and safety of omalizumab in CSU patients, focusing on the factors predicting the response patterns. Methods: This was a retrospective cross-sectional single-center study investigating CSU patients treated with omalizumab for at least 6 months between September 2015 and February 2023. Patients were evaluated regarding demographics, clinical findings, baseline laboratory parameters, treatment outcomes, and side effects. Early and late responders were defined depending on the time for response, within or after 3 months, respectively. Results: Among 82 patients, 75 (91.5%) responded to omalizumab during the first 6 months, classified as early (n = 51) and late responders (n = 24). The IgG anti-thyroid peroxidase (anti-TPO)/total IgE ratio was an independent predictor for determining the speed of response (p < 0.05). Of 29 patients who discontinued omalizumab, 19 (65.5%) experienced relapse with a good response to retreatment (n = 18/19, 94.7%). Early responders relapsed more frequently than late responders (77.3% vs. 28.6%) (p < 0.05). Only mild side effects were observed in a minority of patients (n = 8/82, 9.8%). Conclusion: Omalizumab is an effective and safe treatment in CSU. The IgG anti-TPO/total IgE ratio seems a valuable tool to predict the early and late responders, the former having a higher possibility of relapse upon drug withdrawal.
dc.identifier.doi10.1159/000538291
dc.identifier.endpage793
dc.identifier.issn1018-2438
dc.identifier.issn1423-0097
dc.identifier.issue8
dc.identifier.pmid38626739
dc.identifier.scopus2-s2.0-85191401507
dc.identifier.scopusqualityQ2
dc.identifier.startpage786
dc.identifier.urihttps://doi.org/10.1159/000538291
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23747
dc.identifier.volume185
dc.identifier.wosWOS:001209071400001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofInternational Archives of Allergy and Immunology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectChronic spontaneous urticaria
dc.subjectEarly responder
dc.subjectIgG anti-thyroid peroxidase
dc.subjectTotal IgE
dc.subjectLate responder
dc.subjectOmalizumab
dc.titlePredicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu